IMC1C11

chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation; used for treatment of patients with liver metastases from colorectal carcinoma (in Phase I trial 1/2004)

Also Known As:

IMC-1C11

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        IMC1C11: 4
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        IMC1C11: 4
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        IMC1C11: 4

Experts

1.	Dias, S: 2 articles (03/2003 - 08/2000)
2.	Hattori, K: 2 articles (03/2003 - 08/2000)
3.	Rafii, S: 2 articles (03/2003 - 08/2000)
4.	Witte, L: 2 articles (03/2003 - 08/2000)
5.	Zhu, Z: 2 articles (03/2003 - 08/2000)
6.	Hicklin, Daniel J: 1 article (11/2004)
7.	Moore, Malcolm A S: 1 article (11/2004)
8.	Teruya-Feldstein, Julie: 1 article (11/2004)
9.	Wang, Eunice S: 1 article (11/2004)
10.	Wu, Yan: 1 article (11/2004)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 04/01/2003 - "In a dose-escalation, single-agent study of IMC-1C11, we enrolled 14 patients with colorectal carcinoma and hepatic metastases. " 04/01/2003 - "A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma."
2.	Neoplasm Metastasis (Metastasis) 04/01/2003 - "In a dose-escalation, single-agent study of IMC-1C11, we enrolled 14 patients with colorectal carcinoma and hepatic metastases. " 04/01/2003 - "A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma."
3.	Leukemia 08/01/2000 - "Injection of IMC-1C11 inhibited proliferation of xenotransplanted human leukemias and significantly increased the survival of inoculated mice. " 03/01/2003 - "A chimeric anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-1C11, was shown to be able to inhibit VEGF-induced proliferation of human leukemia cells in vitro, and to prolong survival of nonobese diabetic-severe combined immune deficient (NOD-SCID) mice inoculated with human leukemia cells. "
4.	Neoplasms (Cancer) 11/01/2004 - "Treatment with 6.12 or DC101 (targeting tumor VEGFR-1 and host VEGFR-2) reduced established DLBCL xenograft growth, whereas treatment with IMC-1C11 or MF-1 (targeting tumor VEGFR-1 and host VEGFR-1) had no effect. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)